Drug Discovery Weekly — April 5, 2026

FDA & Regulatory Decisions

Q1 2026 FDA Novel Drug Approvals: A Quarter in Review

According to BioPatrika's comprehensive analysis published just two days ago, the FDA's Q1 2026 novel drug approval class spanned key therapeutic areas including oncology, rare diseases, and dermatology. The report highlights important trends in the regulatory landscape heading into Q2.

Tariff Pressures on Pharma Supply Chain — With Loopholes

The Trump administration revived pharma-specific tariffs at 100% under "Section 232" national security levies — but critically, analysts note these do not apply to a wide array of drugs. "The overall threat to the sector should be low," according to one analyst quoted by BioPharma Dive. The report, published just two days ago, highlights that most pharmaceutical products remain outside the scope of the new tariffs, limiting their practical impact on industry operations.

Late-Stage RA/QA Regulatory Developments — March/April 2026

The FDA Group's insider newsletter, published two days ago, rounds up key RA/QA regulatory news from late March 2026, noting ongoing agency activity across multiple development programs.

1 sources

biopatrika.com

biopatrika.com

Clinical Trial Spotlight

Capricor's HOPE-3 Phase 3 Trial: Deramiocel Meets Primary and Key Secondary Endpoints in Duchenne Muscular Dystrophy

In arguably the most significant clinical readout this week, Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 study of deramiocel in Duchenne Muscular Dystrophy (DMD). The randomized, double-blind, placebo-controlled study (n=106) met its primary endpoint (PUL v2.0) with statistical significance (p=0.03), and also met the key secondary cardiac endpoint (LVEF), again with statistical significance (p=0.04).

These results are highly meaningful for DMD patients, a devastating progressive disease with limited treatment options. The dual significance — both functional motor and cardiac endpoints — strengthens the regulatory case for deramiocel substantially.

Karyopharm's SENTRY Phase 3 Trial in Myelofibrosis: Mixed Results

Published approximately two weeks ago (and thus within the context period for background), Karyopharm Therapeutics' Phase 3 SENTRY trial in myelofibrosis delivered a split verdict: the trial met its first co-primary endpoint, demonstrating statistically significant improvement in spleen volume reduction, but did not meet its second co-primary endpoint of Absolute Total Symptom Score (Abs-TSS). Similar symptom improvement was observed across both arms relative to baseline. The data may support a regulatory path for the spleen volume indication, even as the symptom control story remains unresolved.

Neurology Trial Readouts on the Horizon in Early 2026

NeurologyLive published a comprehensive guide approximately one week ago to key neurology trial readouts to watch in early 2026. The analysis highlights studies across Alzheimer's, neurodegeneration, and other CNS conditions, noting key baseline demographics such as CDR-SB mean scores as primary endpoints of interest.

Deals & Pipeline Moves

BioMarin Acquires Amicus Therapeutics for $4.8 Billion in All-Cash Deal

The week's most consequential transaction: BioMarin Pharmaceuticals has reached a definitive agreement to acquire Amicus Therapeutics in an all-cash deal worth $4.8 billion, PharmExec reported one day ago. The acquisition significantly expands BioMarin's rare disease portfolio, adding Amicus' established Fabry and Pompe disease franchises — areas where Amicus has been a leader. The deal also brings late-stage pipeline upside and is expected to immediately accelerate revenue growth while strengthening long-term financial performance for BioMarin.

Strategic rationale is compelling: BioMarin, already a rare disease heavyweight, gains two commercially proven therapies in ultra-rare metabolic disorders, deepening its market position in an area with high barriers to entry and strong pricing power. Amicus' CFO and management team had been executing well on Pompe disease in particular, making this a premium acquisition of a commercially-ready asset suite.

Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion — Now Eyeing Early-Stage Assets

Following closely on the heels of the BioMarin announcement, Biogen completed its $5.6 billion acquisition of Apellis Pharmaceuticals, bringing two marketed complement therapies into its portfolio and strengthening its immunology position. Now, just days after the deal closed, Biogen's CFO Robin Kramer told BioPharma Dive that the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals, with an eye toward early-stage assets in immunology, rare diseases, and neuroscience.

This signals Biogen's intent to remain aggressive on the M&A front even after a significant transaction, underscoring the broader industry trend of consolidation in the rare disease and immunology space.

Analysis: Development of the Week

BioMarin's $4.8B Amicus Acquisition — Why This Deal Reshapes the Rare Disease Landscape

The Transaction

BioMarin's $4.8 billion all-cash deal for Amicus Therapeutics is the defining pharma event of this week. Coming on the heels of Biogen's $5.6 billion Apellis acquisition, it confirms what analysts at BioSpace predicted just three days ago: "Pharma's M&A train is on track for record highs with more deals to come." Following a flurry of deals from Eli Lilly (Terns Pharma, ~$6B), Merck, and Biogen over the past several weeks, analysts are now watching Novartis, Amgen, and AbbVie as the next likely acquirers.

Why Amicus?

Amicus occupies an enviable position: a pure-play rare disease biotech with two marketed products (migalastat for Fabry disease, cipaglucosidase alfa for late-onset Pompe disease) that generate growing recurring revenue in conditions with essentially no adequate treatment alternatives. For BioMarin — which knows lysosomal storage disease better than almost anyone — these franchises are an obvious strategic fit. There is likely significant commercial synergy given overlapping specialist physician networks and patient registries.

Competitive Landscape Implications

The rare disease space is consolidating rapidly. With BioMarin absorbing Amicus and Biogen taking Apellis, the mid-cap rare disease biotech universe is thinning. Companies like Ultragenyx, Sarepta, and Alexion (now AstraZeneca) are likely watching carefully. Patients stand to benefit from the deeper resources of larger acquirers — but smaller pure-play rare disease biotechs may find themselves under acquisition pressure, potentially accelerating timelines for therapies in development.

Patient Impact

For patients with Fabry disease and Pompe disease, BioMarin's acquisition provides continuity and likely increased investment in clinical development programs. BioMarin has a track record of investing heavily in post-marketing evidence generation and rare disease patient communities — a positive signal for the Amicus patient base.

What to Watch

Upcoming PDUFA Dates and Key Catalysts in Q2 2026:

1. Multiple Q2 2026 FDA Decisions — HCPLive identified six FDA decisions to watch in Q2 2026, including treatments for Alzheimer's disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity. Several PDUFA dates fall in April and May 2026.

2. Capricor Therapeutics BLA Filing for Deramiocel — Following the positive HOPE-3 Phase 3 readout this week, watch for Capricor's BLA submission timeline. With both primary and key secondary endpoints met, analysts will be parsing whether the company files for accelerated review.

3. Karyopharm SENTRY Follow-Up Data — The myelofibrosis SENTRY trial's mixed results (spleen volume yes, symptom score no) will require further regulatory discussions. Watch for Karyopharm's update on a potential NDA pathway based on the spleen volume endpoint alone.

4. Additional M&A Announcements — With Novartis, Amgen, and AbbVie flagged as likely next movers, watch for deal announcements from these large-caps over the coming weeks, particularly targeting rare disease and immunology biotechs.

5. Pharma Tariff Exemption Clarifications — The Section 232 tariff implementation remains in flux, with broad exemptions already in place. Watch for further regulatory guidance clarifying which products are covered — critical for global supply chain planning.